TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib

详细信息    查看全文

• 作者：Kung-Chu Ho ; Yu-Hua Dean Fang…
• 关键词：Lung cancer ; Erlotinib ; FDG ; PET ; Tumor response ; Survival ; Outcomes
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：43
• 期：12
• 页码：2155-2165
• 全文大小：1,698 KB
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nuclear Medicine
  Imaging and Radiology
  Orthopedics
  Cardiology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1619-7089
• 卷排序：43

文摘

PurposeIn this retrospective review of prospectively collected data, we sought to investigate whether early FDG-PET assessment of treatment response based on total lesion glycolysis measured using a systemic approach (TLG-S) would be superior to either local assessment with EORTC (European Organization for Research and Treatment of Cancer) criteria or single-lesion assessment with PERCIST (PET Response Criteria in Solid Tumors) for predicting clinical outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. We also examined the effect of bone flares on tumor response evaluation by single-lesion assessment with PERCIST in patients with metastatic bone lesions.